

Unlocking the potential of advanced therapies for hearing loss



May 2023

SENSORION

Our vision is to help people with inner ear hearing disorders to live life with unlimited connections



DISCLAIMER

- This document has been prepared by Sensorion (the "Company") and is provided for information purposes only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris. No reliance may be placed for any purposes whatsoever on the information or opinions contained in this document or on its accuracy or completeness.
- This presentation does not constitute an offer to sell, a solicitation of, or an invitation to subscribe for or to buy, securities of Sensorion in any jurisdiction.
- The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions contained herein which are subject to change without prior notice.
- The information contained in this document has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.
- This document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information.
- This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company's future performance and the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include those discussed or identified in the "Risk Factors" section of our 2022 Annual Financial Report published on March 30, 2023, and available on our website (www.sensorion.com). Even if the Company's financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document.
- Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in the tables may not necessarily equal the sum of the individually rounded figures, amounts or percentages.
- All persons accessing this document must agree to the restrictions and limitations set out above.

Sensorion: Overview

- Sensorion currently develops two Gene Therapy (GT) programs in the ear, targeting monogenic forms of deafness with pediatric and adult onset:
 - OTOF-GT caused by mutations of the gene encoding for otoferlin, EU & US ODD, US RPDD
 - GJB2-GT related to mutations in GJB2 gene (candidate selected)
 - Prospective natural history studies ongoing, strong European eco-system in place
- Oral small molecule asset SENS-401, for the prevention and treatment of hearing loss:
 - Sensorion and Cochlear Ltd collaboration (ongoing clinical Proof-of-Concept study)
 - **Cisplatin-Induced Ototoxicity** (ongoing clinical Proof-of-Concept study)
 - Sudden Sensorineural Hearing Loss (completed Phase 2 study)
- Exclusive relationship with Institut Pasteur in the field of hearing genetics, several GT programs initiated under strategic collaboration
- Strong partnerships with key players in hearing care and devices, including Necker Hospital (Paris, FR), Cochlear Ltd. (ASX listed) and Sonova (global hearing aid market leader)
- Strong shareholder base including leading blue-chip investors; listed on Euronext Growth

We Want People With Inner Ear Hearing Disorders To Live Life With Unlimited Connections



1. Make OTOF-GT the Standard of Care

- Replacing cochlear implantation
- Transforming lives for babies


2. Develop GJB2-GT and Other GT Products

Addressing adolescent and adult populations

3. Enjoy Life to the max with 24/7 Access to Sound


- Kids navigating with ease in school
- Adults effortlessly adjusting to the different voices of multiple talkers in workplace, social spaces
- Reducing cognitive effort and mental workload

Our Vision: A Global Franchise Establishing Leadership In The Hearing Space





Together With Best-In-Class Partners We Can Transform the Current Standard of Care



Sensorion is Well Positioned to Transform the Hearing Landscape - Institut Pasteur Partnership Provides GT Pipeline

GENE THERAPY

Otoferlin deficiency (OTOF-GT)

CTA enabling studies

• Hearing restoration in DFNB9 pediatric patients

Connexin 26 deficiency (GJB2-GT)

Candidate selected

- Hearing restoration in DFNB1 pediatric patients
- Hearing restoration in **childhood onset** of hearing loss linked to GJB2 mutations
- Hearing restoration in early onset severe **presbycusis** linked to GJB2 mutations

SMALL MOLECULE: SENS-401

Sudden Sensorineural Hearing Loss (SSNHL)

AUDIBLE-S Ph2 study completed

- Meaningful and statistically significant effect on PTA change over time in a large idiopathic population
- Complete PTA recovery in 50% of treated patients

Cisplatin-Induced Ototoxicity (CIO)

NOTOXIS Ph2 study ongoing

 Assess prevention of the ototoxicity induced by Cisplatin in patients with neoplastic disease

Cochlear Implantation (CI)

Ph2 study ongoing

- Assess preservation of the residual hearing after cochlear implantation
- Evaluate the presence of SENS-401 in the perilymph

Sensorion's Portfolio Of Advanced Hearing Loss Therapies

	Product	Indication	Discovery	In-vivo POC	Preclinical	Phase 1	Phase 2	Phase 3	Upcoming Milestones (estimated)
	OTOF-GT*	Otoferlin Deficiency							Clinical Trial Application Q2 2023
RESTORE	GJB2-GT*	Adult onset (presbycusis)				- 			Candidate Selected
RES	GJB2-GT*	Pediatric progressive				1 1 1 1			Candidate Selected
	GJB2-GT*	Congenital onset							Candidate Selected
PREVENT	SENS-401	Hearing preservation after CI				1 1 1 1	Cochlear-		Preliminary Results mid 2023
PRI	SENS-401	Cisplatin-Induced Ototoxicity							Preliminary Results H2 2023
TREAT	SENS-401	SSNHL		- 		- 			Exploring Partnering Opportunities

3SBio has a right of first refusal with respect to licensing in Greater China of SENS-401 (except in combination with cochlear implants) and OTOF-GT *Option to obtain a licence from Institut Pasteur (pre-defined financial terms and other terms to be negotiated)

An Experienced Leadership Team and SAB



NAWAL OUZREN Chief Executive Officer

SENSORION (Since 2017)

SHIRE (2016-2017) Head of the Global Genetic Diseases Franchise

BAXALTA (2014-2016) Vice President of the Global Hemophilia Franchise



GÉRALDINE HONNET Chief Medical Officer

SENSORION (Since 2020)

GENETHON (2011-2020) Director of Development

TRANSGENE (2007-2011) Responsible of development of infectious diseases programs



DAVID LAWRENCE Chief Financial Officer

SENSORION (Since 2023)

VALNEVA (2017-2021) Chief Financial Officer

SYNPROMICS (2011-2019) Co-Founder & Board member

GSK/CHIRON/ACAMBIS (1988-2006)





SENSORION (Since 2020)

CELLECTIS (2016-2020) Program Leader & Preclinical Manager

OTR3 (2008-2015) R&D Director & Clinical Project

Director & Clinical Project Manager





LAURENT DESIRECHRISTINE LE BECHead of Preclinical DevelopmentHead of CMC Gene Therapy

SENSORION

(Since 2020) YPOSKESI

(2017-2020) Head of Cellular & Molecular Biology Unit

> DIAXONHIT (2012-2017)

R&D Executive Director

SENSORION (Since 2020)


GENETHON

(1996-2020) Head of CMC Analytical Department

Scientific Advisory Board

- Pr Christine Petit, France, Chair SAB, Professor, Institut Pasteur
- Pr Alain Fischer, France, Professor, Collège de France
- Dr. Robert Dow, UK, Chief Medical Officer, Scendea
- Dr. Paul Avan, France, Head of the Center for Research, Hearing Institute (Paris)
- Dr. Diane Lazard, France, Principal Associate Investigator, Hearing Institute (Paris)
- **Dr. Hernán López-Schier**, Germany, Senior Group Leader & Research Unit Director at the Helmholtz Center (Munich)

We Have Established Strong Internal Capabilities To Ensure Successful Execution







CMC GENE THERAPY FACILITIES

- **Process development**: non-GMP manufacturing from small scale up to 50L in bioreactor
- Analytical development: development of productspecific analytical methods, inhouse generic assays to support process development and AAV manufacturing



REGULATORY EXPERTISE

- Develop regulatory strategies to ensure expedited product development including gene therapy
- Regulatory Agency interaction (EU/US)
- Shape the treatment guidelines and standardize clinical endpoints

Our Team has Significant Experience in Gene Therapy Clinical Development

The team has been involved in 15+ programs from preclinical to BLA filing...



... across different organs and indications...

... using different technologies...



... with multiple organizations



GENE THERAPY PROGRAMS



Sensorion's Gene Therapy Programs Target Rare Auditory Diseases

FIRST PROGRAMS RESULTING FROM THE INSTITUT PASTEUR COLLABORATION

OTOFERLIN DEFICIENCY	GJB2-RELATED HEARING LOSS
 Patients with mutations in OTOF suffer from severe to profound sensorineural prelingual non-syndromic hearing loss 	We have identified three forms of hearing loss associated with <i>GJB2</i> gene mutations:
 Otoferlin deficiency could be responsible for up to 8% of all cases of congenital hearing loss 	Early onset of severe presbycusisChildhood onset
Prevalence ~20,000 in the USA + EU	 Congenital onset
 Incidence ~1,100 per year in USA + EU 	 ~100,000 patients between 30 and 69 years old thought to be affected by a monogenic form of presbycusis due to GJB2 mutations
EU and US ODD	Prevalence of congenital and childhood onset forms are estimated to be
 US FDA has granted RPDD 	around 200,000 patients as around 50% of autosomal recessive non syndromic hearing loss cases are thought to be from <i>GJB2</i> mutations
Sources: Akil et al. 2019 (<u>link</u>), Orphanet (<u>link</u>), NIH (<u>link</u>), company estimates ba & Co 2019 report, Institut Paste	

DELAYED DIAGNOSIS – NOT SUSPECTED AT FIRST SIGHT

GENE THERAPY HAS A LIFE-CHANGING POTENTIAL FOR THESE AUDITORY DISEASES

Aiming To Develop Best-in Class And First-in Class Gene Therapy

CRITERIA	SENSORION
AAV capsid selected for high-level of target cells specificity	
GT product showing high level of target cells transduction	
Limited off-target tissue biodistribution	
Surgical approach developed and mastered by ENTs surgeons	
Natural History Study preparing execution of the clinical trial	
Regular engagement with regulatory agencies	

Gene Therapy Pediatric Indications Have Blockbuster Sales Potential

OTOF-GT is the perfect pilot program


- Well understood biology and pathology of the otoferlin deficiency
- Full functionality of the remaining chain
- High specificity for the inner hair cells (IHCs), no off-target effect expected

- OTOF-GT will be the pilot program demonstrating that GT is a relevant medical approach for the inner ear
- OTOF-GT will establish understanding of GT in the inner ear by the Regulators and the Payers for future GT programs
- Medical plausibility and target population have been confirmed through :
 - ✓ Orphan Drug Designation in the US and EU
 - ✓ Rare Pediatric Disease Designation with eligibility for voucher in the US



Sources: Sensorion, AT Kearney market research


OTOF Gene Encodes Otoferlin, A Key Ca2⁺ Sensor Protein



Model illustrating calcium regulation of otoferlin/SNARE interaction in the hair cell – Adapted from Ramakrishnan et al. 2014

OTOF is the gene coding for the otoferlin protein, a Ca2⁺ sensor for vesicle fusion and vesicle pool replenishment at auditory hair cell ribbon synapses


Dual AAV-OTOF Resulted In IHCs Specific Expression And Hearing Restoration In DFNB9 Mice



Improved


Restored

Optimized Surgical Procedure Leads To IHC Specific AAVdelivered Transgene Transduction In Mature NHP Cochlea



IHC

neutralizing antibodies (measured in blood before injection) and the average of GFP⁺ cells



MyoVIIa Actin GFP

Surgical approach

- Surgical procedure is **similar to** cochlear implantation and well mastered by ENTs surgeons
- Optimized surgery uses stapedotomy procedure to maximize target cells exposure along the full length of the tonotopic axis
- New injection system device under development

Lahlou et al. ARO 2022 link

Otoferlin "Audinnove" Consortium Provides Privileged Access To Patients And Surgeons

Audinnove consortium received Hospital-University Research (RHU) prize:

- The consortium is eligible to receive up to €9.7m to develop a Gene Therapy program addressing otoferlin deficiency
- Audioferlin: Natural History Study: clinical evaluation and selection of patients
- Database compilation with genotypic and phenotypic characterization of children with congenital hearing loss
- Phase 1/2 Gene Therapy study (financing up to 1st patient in the clinical study)

Audinnove consortium is key to the understanding of the epidemiology and to build awareness of the emerging gene therapies

Necker-Enfants Malades Hospital

• The first dedicated pediatric hospital in the world

The Reference Center for Genetic Deafness at Necker coordinates the French and European genetic deafness networks



Audinnove is financed by the French State, via the National Research Agency through the "Investing for the future" program (ref: ANR-18-RHUS-0007)

OTOCONEX: expanding the Natural History Study across Europe



OTOF Gene Therapy Program Status – Progressing On Track

POC data in mouse & POC Submission of European Natural History Study OTOCONEX preliminary data in NHPs Product development and

Delivery of batches for toxicology study mid-2022

Clinical Trial Application Q2 2023



Advice from regulatory authorities

manufacturing agreement

Connexin 26: A Gap-junction Protein Encoded By GJB2 Gene and Responsible for Tissue Homeostasis Mutations in the Gene Lead to Deafness


- *GJB2* is the gene encoding for the **Connexin 26** protein; one of 20 known connexins in humans and almost endemic to the cochlea (together with Cx30); **a hexamer of 6 proteins forms Gap Junctions**
- Gap Junctions are **key for the intercellular exchange of molecules** (miRNA, glucose, ions, etc.) hence responsible for **tissue homeostasis**
- *GJB2* cDNA = 681 bp compatible with the use of a **single AAV**
- More than 100 recessive mutations origin Cx26 truncation / deletion leading to non-syndromic hearing loss and deafness
- *GJB2* mutations are the **most prevalent form of congenital deafness** (DFNB1)
- Children are usually **diagnosed during routine newborn screening** and current SoC is cochlear implantation prior to language acquisition
- Prof. Christine Petit observed in an epidemiology study that some patients demonstrating early onset of severe presbycusis carried GJB2 mutations^[1]

Connexon 3.5 nm Connexin Intercellular pore

> Schematic representation of a gap junction – adapted from Kemperman, Hoefsloot and Cremers J R Soc Med 2002;95; 171-177

[1]: Boucher et al. 2020

Candidate Selected Prevents Hearing Loss in Relevant Mouse Model



GJB2 Gene Therapy Program Next Steps



Submission of Natural History Study in collaboration with Sonova

Candidate selection Q2 2023



Preclinical IND enabling studies

SMALL MOLECULE PROGRAMS




SENS-401: Multiple Indications To Treat And Prevent Hearing Loss

	Indication	Discovery	In vivo POC	Preclinical	Phase 1	Phase 2	Phase 3
SENS-401	Hearing preservation						
	after						
	cochlear implantation					Cochlear™	
	Cionlatin						
	Induced Ototoxicity						
	Sudden						
SENS-401 SENS-401							

*"Patriot" Consortium (IRBA, Sensorion, Echodia, Institut Pasteur) awarded up to €10.8m non dilutive financing by French government, staged over the duration of the project. Sensorion will receive up to €5.6m to further develop SENS-401 in SSNHL French army

SENS-401 - A Portfolio With Potential Blockbuster Value



SENS-401 SSNHL clinical data and insight **derisk** further development of SENS-401 in other indications

Sudden Sensorineural Hearing Loss (SSNHL) Is A Severe Disease Affecting More Than 200,000 Patients Per Year

WHAT IS SSNHL?

The sudden onset of a significant hearing loss due to dysfunction of the cells of the cochlea and central auditory structures.

Hearing loss develops over less than 72 hrs, hearing sensitivity is reduced by at least 30 dB (1,000 fold) in the affected ear(s).

>70% of cases are idiopathic, known causes include noise/head trauma, ischemia, infection.

>50% of patients suffer from permanent disabling hearing loss, mostly those with initial severe/profound hearing loss.

Complications significantly impact quality of life due to:


- Difficulties in communicating, social isolation, cognitive decline
- Accompanying tinnitus

Incidence: 27-35 per 100,000 (218,000 patients in 2017 in G7 countries)¹

¹ Company/ estimates based on publicly available data (in the US, Japan, Germany, France, the UK, Italy and Spain)

SENS-401 SSNHL Program: Phase 2 Design

A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL




Primary endpoint definition:

"...change in pure tone audiometry (PTA); average of the hearing threshold of 3 contiguous most affected hearing frequencies in decibels in the affected ear from baseline to the end of treatment visit (Visit 5/D28±3)"


SENS-401 Plasmatic Exposure

Plasmatic concentration (Pre-dose at Day 14 and Day 28)





SENS-401 Induces Complete PTA Recovery In 50% Of Patients



Although Primary Endpoint Not Met, Data Supports And Informs Further Clinical Development

PTA improvement from baseline compared to placebo on per protocol idiopathic SSNHL

5 change from baseline (dB) 0 -5 **Estimate PTA** -10 SENS-401 treatment duration -15 Day 84 Day 7 Day 28 Day 14 *a:p<0.05 *b:p=0.0566 Legend SENS-401 High dose vs Placebo SENS-401 Low dose vs Placebo

	Day 7	Day 14	Day 28	Day 84
High dose	N= 21	N= 23	N= 22	N= 17
Low dose	N= 26	N= 26	N= 26	N= 21
Placebo	N= 25	N= 28	N= 27	N= 25

– – – Primary analysis

Comparing SENS-401 treatment groups to Placebo at **Day 28** with a **target of an improvement of 15 dB**.


 — — — 10 dB change from baseline considered as clinically meaningful.

Sub-population

Homogeneous idiopathic population of patients treated with corticosteroids.

• Statistically significant effect on PTA change with more than 10 dB change from baseline vs placebo observed over time in homogeneous idiopathic population of patients treated with corticosteroids.

SENS-401 Effect Is More Pronounced In A Profound Hearing Loss Sub-group (PTA ≥ 80 Db)



	Day 7	Day 14	Day 28	Day 84
High dose	N= 11	N= 11	N= 9	N= 9
Low dose	N= 11	N= 11	N= 9	N= 9
Placebo	N= 14	N= 15	N= 15	N= 13

--- Primary analysis

Comparing SENS-401 treatment groups to Placebo at Day 28 with a **target of an improvement of 15 dB**.

— — – **10 dB change from baseline** considered as clinically meaningful.

Sub-population

Homogeneous idiopathic population of patients with profound hearing loss (PTA \ge 80 dB) treated with corticosteroids.

- SENS-401 induces a significative PTA change of at least 19 dB at day 28 and up to 25 dB at Day 84 allowing a reduction of the hearing loss degree from profound to mild hearing loss.
- A better response was observed in both treatment groups with a continuous improvement between Day 28 and Day 84.

SENS-401 SSNHL Phase 2 Results Summary Seeking Partners For Late-Stage Development And Commercialization

AUDIBLE-S SECONDARY ENDPOINT RESULTS

- Complete PTA recovery is achieved in 50% of the SENS-401 treated patients
- SENS-401 shows a clinically meaningful and statistically significant effect on PTA change over time in a large homogeneous idiopathic population of patients treated with corticosteroids
- SENS-401 induces a significative PTA change of at least 19 dB at day 28 and up to 25 dB at Day 84 allowing a reduction of the hearing loss degree from profound to mild
- The change in PTA translates into functional improvement evidenced with speech audiometry tests
- Safe and well tolerated in 115-patient SSNHL study; primary endpoint not met
- Responder rate is always better in the treated group compared to Placebo and difference with Placebo increases over time

Cisplatin Administration for Chemotherapies Damages the Inner Ear and Leads to Hearing Loss, Tinnitus and Dizziness

WHAT IS CIO?

Hearing loss caused by cisplatin administration as chemotherapeutic treatment. Risk factors include young age as well as individual and cumulative cisplatin doses.

CIO leads to permanent inner ear problems in 50-60% of adult cases and in 90% of pediatric cases.

These complications significantly impact patients' quality of life due to:

- Hearing loss, tinnitus and dizziness impacting daily life activities
- Problems in language acquisition and learning for pediatric patients
- Difficulties in communicating, social isolation, cognitive decline

Potential treatments must not interfere with cisplatin efficacy.


Incidence of cisplatin treated patients: 500,000 patients in 2025 in G7 countries¹



¹ Company/ estimates based on publicly available data (in the US, Japan, Germany, France, the UK, Italy and Spain)


SENS-401 Phase 2a Proof-of-Concept Study First Data Expected H2 2023

A Phase 2a, Multicenter, Randomized, Controlled, Open-label Study to Evaluate the Efficacy of SENS-401 to Prevent the Ototoxicity induced by Cisplatin in Adult Subjects with a Neoplastic Disease




SENS-401 To Preserve Residual Hearing After Cochlear Implantation

COMBINATION OF COCHLEAR IMPLANT WITH SENS-401 TO PREVENT CELL-DEATH POST COCHLEAR IMPLANT PROCEDURE




Source: Cochlear® 2018 investor day (link)



¹Cochlear[®] FY21 Result Presentation (<u>link</u>) ²Market estimates (<u>link</u>)

SENS-401 Study Commenced In Sept. 2022 First Data Expected Mid-2023

A Phase 2a, Multicenter, Randomized, Controlled, Open-label Study



To evaluate the presence of SENS-401 in the perilymph

Change of hearing threshold from baseline to the end of the study in the implanted ear at several frequencies

Cochlear^{*}

SENS-401 Program Key Milestones, Data Readouts Mid 2023





SENS-401 CIO NOTOXIS CTA amendment approved Oct 2022

SENS-401 CIO NOTOXIS - preliminary results H2 2023

SENS-401 combo with cochlear implants - preliminary results mid 2023

Sensorion Newsflow [estimated timelines]

Mid-2022 – OTOF-GT: delivery of batches for toxicology study H2 2022 – OTOF-GT: EMA's positive opinion for ODD H2 2022 – SENS-401 CIO: NOTOXIS CTA study amendment approval H2 2022 – OTOF-GT: FDA approval for RPDD H2 2022 – OTOF-GT: FDA approval for US ODD • April 6, 2023 – Sensorion to host a Gene Therapy R&D day Q2 2023 – GJB2-GT: candidate selection Q2 2023 – OTOF-GT: submission of the Clinical Trial Application (CTA) Mid-2023 – SENS-401 in combination with cochlear implantation: preliminary results • H2 2023 – SENS-401 CIO: NOTOXIS preliminary results

THANK YOU

E: contact@sensorion-pharma.com

